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Abstract: Empyema thoracis causes high mortality, and its incidence is increasing in both 
  children and adults. Parapneumonic effusions (PPEs) develop in about one-half of patients 
  hospitalized with pneumonia, and their presence increases mortality by about four-fold. PPEs can 
be divided into simple PPEs, complicated PPEs, and frank empyema. Two guideline   statements 
on the management of PPEs in adults have been published by the British Thoracic Society 
(BTS) and the American College of Chest Physicians; a third guideline statement published 
by the BTS focused on management of PPEs in children. The two adult guideline statements 
recommend drainage of the pleural space in complicated PPEs and frank empyema. They also 
recommend the use of intrapleural fibrinolysis in those who do not show   improvement. The pedi-
atric guideline statement recommends adding intrapleural fibrinolysis to those treated by tube 
thoracostomy if they have loculated pleural space or thick pus. Published guideline statements on 
the management of complicated PPEs and empyema in adults and children recommend the use 
of intrapleural fibrinolysis in those who do not show improvement after pleural space drainage. 
However,   published clinical trial reports on the use of intrapleural fibrinolysis for the treatment 
of pleural space sepsis   suffer from major design and methodologic limitations. Nevertheless, 
published reports have shown that the use of intrapleural fibrinolysis does not reduce mortal-
ity in adults with parapneumonic effusions and empyema. However, intrapleural fibrinolysis 
enhances drainage of infected pleural fluid and may be used in patients with large collections 
of infected pleural fluid causing breathlessness or respiratory failure, but a proportion of these 
patients will ultimately need surgery for definite cure. Intrapleural streptokinase and urokinase 
seem to be equally efficacious in enhancing infected pleural fluid drainage in adults. In most of 
the published studies in adults, the use of intrapleural fibrinolysis was not associated with serious 
side effects. There is emerging evidence that the combination of intrapleural tissue plasminogen 
activator (tPA) and deoxyribonuclease (DNase) is significantly superior to tPA or DNase alone or 
placebo in improving pleural fluid drainage in patients with pleural space infection. In children, 
intrapleural fibrinolysis has not been shown to reduce mortality, but has been shown to enhance 
drainage of the pleural space and was safe. In addition, two prospective, randomized trials have 
shown that intrapleural fibrinolysis is as effective as video-assisted thoracoscopic surgery for 
the treatment of childhood empyema and is a more cost-effective treatment and therefore should 
be the primary treatment of choice.
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Introduction
Empyema thoracis has been recognized since ancient times, and in spite of modern 
therapeutic interventions is still a cause of high mortality.1 In recent years, the incidence 
of empyema has been increasing in both children and adults, and the cause of this Clinical Pharmacology:   Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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surge remains unknown.2 Most cases of empyema complicate 
either community- or hospital-acquired pneumonia, but some 
develop without pneumonia, ie, so-called primary empyema, 
and a proportion are iatrogenic. Parapneumonic effusions 
(PPEs) develop in up to 57% of patients hospitalized with 
bacterial pneumonias.3–5 The presence of PPEs increases 
mortality in these patients by about three- to six-fold.4,6
Pathophysiology of parapneumonic 
effusions
The American Thoracic Society described three stages in the 
natural course of empyema, ie, the exudative, fibrinopurulent, 
and organizing phases.7 In the exudative phase, pleural fluid 
is derived from pulmonary interstitial fluid that is associated 
with lung infection and inflammation. This fluid crosses the 
visceral pleura and accumulates in the pleural space and is 
usually not infected. The clinical correlates of the   exudative 
phase are simple PPEs. Simple PPEs have characteristic 
  biochemical and microbiologic features, namely pH . 7.2, 
lactate dehydrogenase , 1000 IU/L, glucose . 2.2 mmol/L, 
and no organisms in culture or Gram stain. Treatment of 
simple PPEs with antibiotics is likely to be adequate, and 
there is no need for pleural fluid drainage.8
Complicated PPEs are clinical correlates of the fibrinopu-
rulent stage. A critical characteristic of the fibrinopurulent 
stage of pleural sepsis is disturbance of the physiologic equi-
librium between clotting and fibrinolysis within the pleural 
space.9 Bacterial invasion across the damaged endothelium 
accelerates the immune reaction, promoting further migra-
tion of neutrophils and activation of the coagulation cascade, 
leading to increased procoagulant and depressed fibrinolytic 
activity.10,11 Several mediators for the activation of the 
coagulation cascade and inhibition of fibrinolysis have been 
suggested. Tumor necrosis factor alpha, for example, has 
been shown to stimulate the release of tissue plasminogen 
activator (tPA) inhibitors from pleural mesothelial cells. It 
has been shown that there are increased levels of tPA-2 and 
depressed levels of tPA during complicated pleural sepsis.12 
Although the exact mechanisms behind the procoagulant 
state still need to be elucidated, their effects are well known, 
ie, pleural surfaces coated with fibrin and fibrin strands with 
secondary adhesions and loculations, and all of these lead to 
impeding of pleural fluid drainage. The inflammatory process 
continues, fueled by more bacterial death and phagocytosis.10 
This combination of events leads to increased lactic acid 
production, causing a drop in pleural fluid pH,13 increased 
glucose consumption, and a rise in lactate dehydrogenase 
levels resulting from leukocyte death. All of these lead to 
the characteristic biochemical and microbiologic changes 
of complicated pleural effusions, namely pH , 7.20, 
  glucose , 2.2 mmol/L, lactate dehydrogenase . 1000 IU/L, 
and possible positive Gram stain and/or bacterial culture. 
If left untreated, complicated PPEs progress to overt pus 
(empyema).
The fibrinopurulent stage is followed by the   organizing 
phase, in which there is proliferation of fibroblasts.10 A solid 
pleural peel replaces the soft fibrin, preventing lung re-
expansion, causing lung function impairment, and creating 
a persistent pleural space.
Guidelines for management  
of parapneumonic effusions
Two guideline statements on the management of PPEs in 
adults have been published by the American College of 
Chest Physicians (ACCP) and the British Thoracic Society 
(BTS).14,15 The two statements reflect different approaches 
to the management of PPEs. However, they agree that all 
complicated PPEs and frank pleural space pus should be 
drained and that patients who do not improve on this treat-
ment may receive intrapleural fibrinolysis or be referred for 
surgical drainage or decortication.14,15
A third guideline statement on the management of PPEs 
in children has been published by the BTS.16 In this docu-
ment, the management of PPEs is planned according to an 
algorithm and recommends that all children with PPEs 
should receive either medical treatment in the form of chest 
tube drainage with pleural fluid sampling for microbiology 
at the same time as chest tube insertion or early surgery in 
the form of video-assisted thoracoscopic surgery (VATS) 
or minithoracostomy. For those who are treated medically, 
if they are noted to have a loculated pleural space or thick 
pus, they should be candidates for intrapleural fibrinolysis. 
If patients do not improve after intrapleural fibrinolysis, they 
should be referred for late surgery.16 In spite of these recom-
mendations, the level of evidence for the use of intrapleural 
fibrinolysis is low.14–16 This paper provides a critical review 
of the existing literature on the use of intrapleural fibrin-
olytic therapy for complicated PPEs and empyema. It also 
reviews emerging evidence on adding DNase to intrapleural 
fibrinolysis in managing complicated PPEs and empyema. 
Articles included in the review were identified by   conducting 
a   Medline search in April 2010. The search terms were 
“empyema” and “parapneumonic effusion”, each linked to 
“fibrinolysis”, “streptokinase”, “urokinase”, and “tissue plas-
minogen activator”. Articles were restricted to the English 
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were reviewed for titles of other possibly relevant articles. 
All articles (controlled or uncontrolled) that used any of the 
fibrinolytic drugs, ie, streptokinase, urokinase, and tPA, in 
the treatment of PPEs or empyema in adults and children 
were included in the review.
Mechanism of action  
of fibrinolytic drugs
Fibrinolytic drugs vary in their mechanism of action. tPA 
induces fibrinolysis of the formed thrombus by preferentially 
activating plasminogen bound to fibrin and does not activate 
systemic plasminogen.17 Streptokinase combines with cir-
culating plasminogen to form an activation complex, which 
causes limited proteolysis of other plasminogen molecules 
to plasmin. Streptokinase activates the conversion of plas-
minogen (profibrinolysin) into plasmin (fibrinolysin), which 
stimulates the conversion of fibrin (insoluble) into fibrin 
fragments (soluble).18 Urokinase is also fibrin-selective and 
is converted to urokinase from prourokinase upon binding 
to fibrin. It directly converts plasminogen into plasmin.19 All 
three drugs have been used in trials of intrapleural fibrinolysis 
in adults and children.
Intrapleural fibrinolytic therapy  
in adults
Intrapleural fibrinolytic treatment of pleural space sepsis was 
first described in 1949 when Tillett and Sherry published their 
seminal article on this subject using streptokinase.20 Since their 
publication, 28 studies on the use of intrapleural fibrinolytic 
therapy for pleural space sepsis in 1280 adults have been pub-
lished, and these reports are summarized in Table 1.21–48
Published studies in adults employed intrapleural uroki-
nase and streptokinase as fibrinolytic agents. Streptokinase 
on its own was used in 16 studies,21–23,25,26,28,29,32,35,38,39,42–44,46,48 
whereas one study used either streptokinase or urokinase.36 
Another controlled study of 44 patients compared streptoki-
nase with normal saline and showed that the use of strepto-
kinase resulted in a higher success rate and reduced surgical 
referral.47 Intrapleural urokinase on its own was used to treat 
pleural space sepsis in eight studies.24,27,30,31,33,34,37,45 Two stud-
ies compared intrapleural urokinase with streptokinase in the 
treatment of pleural space infection.40,41 Bilacerogula et al 
randomized 128 patients with pleural space sepsis to receive 
intrapleural streptokinase, urokinase, or saline. The group that 
received urokinase showed better radiologic clearance and 
drained more fluid.40 However, a similar study that included 
50 patients has shown streptokinase and urokinase to be 
equally efficacious in treating pleural space infection.
The studies of intrapleural fibrinolysis for the treatment 
of empyema and PPEs in adults suffer from three major 
limitations. First, most of these studies are uncontrolled 
observational reports, the methodic limitations of which 
are well known.21–39 Second, they did not have the statistical 
power to measure primary endpoints of clinical interest, 
such as patient mortality, need for surgery, and residual 
lung volume.21–33,35–39,41–46 Third, in many of the published 
reports, the principal endpoint was an increase in pleural fluid 
drainage.21,23–29,32,34,37–43,45 The amount of pleural fluid drained 
is not always an ideal clinical outcome measure because, in 
animal studies, streptokinase has been shown to induce pleural 
fluid accumulation.49 Therefore, enhanced pleural fluid drain-
age should either translate into improved clinical outcome or 
reduced mortality to be an ideal endpoint. Of the published 
work in adults, increased pleural fluid drainage resulted in 
greater improvement in lung expansion or clinical improve-
ment, radiologic improvement, or reduced morbidity in five 
studies.24,38,40,43,45 Of these five studies, three were controlled 
trials.40,43,45 Furthermore, there was partial improvement in 
lung expansion, clinical status, radiologic appearance, or 
reduced morbidity in seven studies.21,23,28,29,32,37,41 Of these, 
only one study was controlled.41 However, it is important to 
note that the amount of pleural fluid drained did not translate 
into reduced mortality in the two studies that assessed volume 
of pleural fluid drained and mortality as endpoints, although 
both were controlled trials.42,47 In fact, only one study has 
shown that streptokinase and early surgical drainage was 
associated with reduced mortality when compared with strep-
tokinase and tube drainage. This study was controlled and 
included 82 patients.46 The use of intrapleural fibrinolysis in 
adults was found to be safe in 13 studies,21,24,26,27,29–31,34,36–39,43 
of which one was controlled.43 Only one study has shown that 
serious adverse events, including chest pain, fever, or allergy, 
were more common in those who received streptokinase, and 
this study was controlled.48
The largest published controlled study on the use 
of intrapleural fibrinolytic therapy for the treatment of 
pleural space sepsis deserves special discussion. This is 
a recently published UK, multicenter, double-blind trial 
including 454 patients with pleural infection.48 Patients were 
randomly assigned to receive either streptokinase 250,000 
U twice daily or placebo for three days. The primary end-
points were death or need for surgical drainage at three 
months. The secondary endpoints were rates of death and 
surgery (analyzed separately), radiographic outcome, and 
length of hospital stay. There was no significant difference 
between the groups who received streptokinase or placebo Clinical Pharmacology:   Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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Table 1 Summary of intrapleural fibrinolysis trials in adults
Reference Type of study Patients (n),  
agent used
Outcome
Bergh et al21 Cohort, single-center 38, streptokinase Increased pleural fluid drainage in all patients;  
lung re-expansion in 79% of patients; safe
Fraedrich et al22 Retrospective 27, streptokinase and  
streptodornase
44% of patients were cured
Mitchell et al23 Retrospective review  
of cases
9, streptokinase Increased pleural fluid drainage in 67% of patients,  
but treatment was successful in 44% of patients only
Moulton et al24 Cohort study,  
single-center
11, urokinase Successful in 92% of patients causing complete  
drainage of pleural space fluid; safe
willsie-ediger et al25 Case reports 3, streptokinase Successful in causing prompt pleural fluid  
drainage in all 3 patients
Aye et al26 Cohort, single-center 14, streptokinase Increased pleural fluid drainage in 93% of patients; safe
Lee et al27 Cohort, single-center 10, urokinase Complete drainage of pleural space was accomplished  
in 90% of patients; safe
Henke et al28 Cohort, single-center 12, streptokinase Increased pleural fluid drainage; radiologic  
improvement in 75% of patients; clinical improvement  
in 67% of patients
Bouros et al29 Cohort, single-center 20, streptokinase Increased pleural fluid drainage; excellent or moderate  
radiologic improvement occurred in 85% of patients; safe
Pollak et al30 Cohort, single-center 8, urokinase Radiologic and clinical resolution or improvement  
in 89% of cases; safe
Robinson et al31 Cohort, single-center; 
some patients were children
13, urokinase Radiologic and clinical resolution in 77% of patients; safe
Taylor et al32 Prospective uncontrolled,  
single-center 
11, streptokinase Increased pleural fluid drainage in all patients;  
re-expansion of lung occurred in 73% of patients
Cohen et al33 Case reports 2, urokinase Resolution of loculated effusions in both patients
Moulton et al34 Retrospective 118 (98 adjunctive urokinase) Increased pleural fluid drainage in 94% of patients; safe
Laisaar et al35 Cohort, single-center 28, streptokinase Seventy-two percent had excellent resolution  
of pleural space collection
Temes et al36 Cohort, two centers 26, streptokinase  
or urokinase
Sixty-two percent of patients had complete resolution  
of symptoms and complete or near complete radiologic  
resolution; safe
Bouros et al37 Uncontrolled, prospective 20, urokinase Increased pleural fluid drainage in all patients;  
excellent radiologic improvement in 65% of patients; safe
Jerjes et al38 Prospective,  
uncontrolled, multicenter
48 (30 with empyema),  
streptokinase
Ninety-two percent of patients had complete resolution  
of pleural collection and adequate radiologic and  
spirometric improvement; safe
Roupie et al39 Retrospective  
review, single-center
16, streptokinase Increased pleural fluid drainage in all patients; complete  
radiologic resolution observed in 87% of patients; safe
Bilaceroglu et al40 Controlled,  
randomized
128, urokinase or  
streptokinase or  
control saline
Increased pleural fluid drainage and radiologic  
improvement in urokinase group compared with  
streptokinase or saline groups
Bouros et al41 Prospective, double-blind 50, streptokinase  
or urokinase
Increased pleural fluid drainage occurred in both  
urokinase and streptokinase groups; clinical  
and radiologic improvement occurred in 92%  
of patients in each group
Chin et al42 Prospective, controlled  
trial, compared adjuvant  
streptokinase with closed  
chest tube drainage 
52, streptokinase Streptokinase increased volume of fluid drained,  
but did not reduce morbidity and mortality
Davies et al43 Randomized controlled  
trial compared intrapleural  
streptokinase with saline
24, streptokinase Streptokinase caused increased pleural fluid drainage  
and greater improvement on chest radiographs  
compared with saline; streptokinase was safe
wait et al44 Randomized trial of vATS  
versus pleural drainage and  
fibrinolytic therapy
20, streptokinase  vATS associated with a higher treatment success,  
shorter hospital stay, and less cost
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Table 1 (Continued)
Reference Type of study Patients (n),  
agent used
Outcome
Bouros et al45 Randomized, double-blind  
study of urokinase  
versus saline
31, urokinase  Urokinase group drained more pleural fluid and  
had better clinical and radiologic improvement
Lim et al46 Nonrandomized,  
prospective, controlled  
time series 
82 (streptokinase with tube  
drainage 29, streptokinase  
with early surgical drainage  
30); 44 (22 streptokinase
Streptokinase with early surgical drainage was  
associated with less mortality and shorter hospitalization
Diacon et al47 Randomized, controlled,  
single-center
and 22 normal saline) Streptokinase caused higher clinical success rate  
and reduced rate of surgical referrals; no difference  
in mortality
Maskell et al48 Double-blind randomized  
trial, 52 centers 
Streptokinase 207  
and placebo 226
Streptokinase did not reduce mortality or rate  
of surgery or length of hospitalization; serious adverse  
effects more in streptokinase groups
Abbreviation: vATS, video-assisted thoracoscopic surgery.
with regard to the proportion of those who died or needed 
surgery (relative risk 1.14; (95% confidence interval [CI] 
0.85–1.54; P = 0.43).48 Regarding the secondary endpoints, 
there was no benefit from streptokinase in terms of mor-
tality, rate of surgery, radiographic outcome, or length of 
hospital stay.48
Intrapleural fibrinolysis versus 
surgery in adults
One small trial has directly compared medical and surgical treat-
ment of complicated PPEs and empyema. Wait et al compared 
tube thoracostomy and fibrinolytic therapy with VATS in a 
prospective randomized trial.44 Twenty patients aged 18 years 
or older with parapneumonic empyema were randomized to 
receive either three doses of 250,000 U each of streptokinase 
administered via tube thoracostomy or VATS. The overall 
mortality rate was 20% and was divided equally between the 
streptokinase and VATS groups. However, the VATS group 
had significantly higher primary treatment success (measured as 
lung expansion), fewer days of chest tube drainage, and fewer 
total hospital days. Of importance, all the streptokinase treatment 
failures (five of nine patients) were successfully treated with 
VATS.44 However, the results of this study need to be interpreted 
in the light of the small sample size and the unusually high failure 
rate (55%) in the medically treated limb. Further appropriately 
powered studies are clearly needed to compare surgical and 
medical treatment of complicated PPEs and empyema. Until 
such studies become available, it is not possible to make definite 
recommendations on the preferability of primary management 
approaches of pleural space sepsis in adults. Generally, patients 
with frank empyema and/or loculations at presentation are more 
likely to require surgery.14,15
Another point of importance is the timing of sequential 
surgical drainage approaches, which has probably varied 
widely among the published studies.14 In a nonrandomized, 
prospective, controlled time series, Lim et al have shown that 
early surgery provided advantages in patients not responding 
rapidly to intrapleural fibrinolysis, but the radiologic assess-
ment performed before drainage was not fully described.46 In 
fact, to this time, there are no established objective criteria 
that define the point at which a patient should be operated on. 
Patients should be considered for surgery if they have residual 
sepsis and persistent pleural collection despite drainage.14,15 
Failure of sepsis to begin to resolve within seven days is 
suggested as an appropriate period after which an opinion 
from a surgeon should be sought.15
It is clear that in spite of guideline recommendations for 
the use of intrapleural fibrinolytic therapy for pleural space 
sepsis in adults,14,15 clinical evidence of benefit remains mar-
ginal. Further support for the lack of evidence of benefit with 
intrapleural fibrinolytic therapy is found in a recent review 
performed by the Cochrane collaboration that describes 
existing data as incomplete and suggests that results should 
be treated with caution because the benefit of intrapleural 
fibrinolytic therapy has not been significant in the subgroup 
of high-quality studies.51
Intrapleural fibrinolytic therapy  
in children
In children, 10 studies of the use of intrapleural fibrinolytic 
therapy in a total of 297 patients have been published and 
are summarized in Table 2.51–60 Published studies in children 
employed intrapleural urokinase, streptokinase, and tPA 
as fibrinolytic agents. Urokinase on its own was used in Clinical Pharmacology:   Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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six studies,52–55,57,59 whereas streptokinase alone was used in 
one study51 and tPA alone in one trial.60 One   retrospective 
study compared urokinase with alteplase and reported a 
treatment success rate of 98% for alteplase and 100% for 
urokinase, but patients who received alteplase drained more 
pleural fluid.58
Like in adults, most of the studies in children were 
uncontrolled observational reports with clear methodic 
limitations.51–54,56–58 Five studies used amount of pleural 
fluid drained as the endpoint, and none of these studies was 
controlled.51,52,54,56,58 In three of these five studies, increased 
pleural fluid drainage resulted in complete resolution of 
empyema, clinical improvement, or clinical success.51,54,58 
It is of note that none of the studies in children demonstrated 
reduction in mortality with the use of intrapleural fibrinolytic 
therapy. The use of intrapleural fibrinolysis in children was 
found to be safe in seven studies,51–54,56–58 and none of the 
pediatric studies reported serious adverse effects.
Intrapleural fibrinolysis versus 
surgery in children
Two prospective, randomized trials in children compared 
thoracoscopic decortication with tube thoracostomy and 
fibrinolysis for empyema.59,60 Their findings were similar. 
Sonnappa et al randomized 60 children with empyema to 
receive either a percutaneous chest drain with intrapleural 
urokinase or primary VATS.59 No significant difference 
between the two groups was found in length of hospital stay 
after intervention, total hospital stay, or radiologic outcome 
at six months after intervention. However, the treatment costs 
for patients in the urokinase arm were significantly lower than 
those for the VATS arm.59 St Peter et al studied 36 patients 
who were randomized to receive either three doses of tPA 
4 mg via a chest tube or decortication via VATS.60 There was 
no difference for days of hospitalization after intervention, 
days of need for oxygen, days until afebrile, or analgesic 
requirements. VATS was associated with significantly higher 
costs. Three patients in the fibrinolysis group subsequently 
required VATS, and two in the VATS group required venti-
latory support, one of whom required temporary dialysis.60 
It can be concluded from these two studies that there is no 
difference in clinical outcome between intrapleural fibrin-
olysis and VATS for the treatment of childhood empyema. 
Intrapleural fibrinolysis is a more cost-effective treatment 
option compared with VATS, and should be the primary 
treatment of choice in children.
Intrapleural DNase
Although streptokinase lyses adhesions, it does not reduce 
pus viscosity.61 It is possible that a combination of agents that 
Table 2 Summary of intrapleural fibrinolysis studies in children
Reference Type of study, settings Patients (n), agent used Outcome
Rosen et al51 Retrospective, single-center 5, streptokinase All empyemas resolved, patients improved  
clinically and drained more pleural fluid; safe 
Stringel et al52 Case reports 2, urokinase Increased pleural fluid drainage; safe 
Kornecki et al53 Case series, single-center 7, urokinase Complete resolution of empyema was  
attained in 86% of patients; safe
Krishnan et al54 Cohort, single-center 14, urokinase All patients had increased pleural fluid  
drainage and resolution of symptoms; safe
Thomson et al55 Double-blind, randomized,  
urokinase versus saline, 10 centers
60, urokinase Significantly shortened hospital stay
Kilic et al56 Case series, single-center 25 (17 urokinase  
and 8 streptokinase)
in 80% of patients there was increased  
pleural fluid drainage and almost complete  
resolution on chest radiography or  
ultrasonography; safe
Barbato et al57 Uncontrolled retrospective  
study, single-center; 17 patients  
received urokinase compared with  
11 historic patients
17, urokinase Seventy percent of patients improved;  
shortened hospital stay; safe
wells et al58 Retrospective review,  
hospital based
71, urokinase or alteplase Treatment success was 98% for alteplase 
and 100% for urokinase; alteplase patients 
drained more fluid; safe 
Sonnappa et al59 Prospective randomized  
trial, single-center
60 (30 urokinase  
versus 30 vATS)
Urokinase is equally efficacious as VATS, but   
a more cost-effective treatment
St Peter et al60 Prospective, randomized 36,   VATS versus tPA tPA is equally efficacious as VATS, but a more   
cost-effective treatment
Abbreviation: vATS, video-assisted thoracoscopic drainage.Clinical Pharmacology:   Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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reduces pus viscosity and breakdown of loculations may be 
more effective in draining the infected pleural space. It is inter-
esting that Tillett and Sherry used two streptococcal products 
in their original work, published more than 60 years ago, on 
the use of intrapleural therapy for the treatment of empyema, 
ie, streptokinase (used as fibrinolysin) and streptococcal 
deoxyribonuclease (used as a depolymerizer of deoxyribonu-
cleoprotein that is abundant in purulent empyematous fluid).20 
Recently there has been an interest in intrapleural DNase as a 
possible candidate to reduce pus viscosity in combination with 
thrombolytic therapy to enhance pus drainage.61 In an animal 
model, the combination of recombinant tPA (alteplase) and 
recombinant human deoxyribonuclease (rhDNase) has been 
shown to be more effective in treating empyema than either 
agent used alone.62 Successful treatment of human empyema 
with intrapleural rhDNase given after intrapleural fibrinolytic 
therapy has been described in at least one case report.63
A multicenter, randomized trial of intrapleural tPA and 
DNase in pleural infection has recently been completed, but 
is currently only reported in abstract form.64 Two hundred and 
ten patients with pleural space infection were randomized 
to receive double-matched placebo, active tPA plus active 
DNase, active tPA plus placebo DNase, or placebo tPA plus 
active DNase for three days. Combination   intrapleural tPA/
DNase was significantly superior to the other combinations 
in improving pleural fluid drainage (95% CI 5%–22.9%; 
P = 0.002). DNase alone appears to be associated with 
increased frequency of surgery and/or death. The proportion 
of patients dying or requiring surgery for their infection was 
higher in the DNase plus placebo group and similar in all 
other groups (number of deaths or surgery tPA/DNase 17.3%; 
placebo/placebo 12.7%; tPA/placebo 15.4%; DNase/placebo 
45.1%, X2 3; P = 0.0001).64 A peer-reviewed full report of 
this trial is awaited.
Conclusion
Empyema thoracis is a cause of high mortality, and its 
occurrence is increasing in both children and adults. BTS 
and ACCP guidelines recommend the use of intrapleural 
fibrinolysis in adults and children with complicated PPEs or 
empyema if they are not improving, have thick pus, or have 
pleural loculations, but the evidence for their benefit is low. 
Published reports on the use of intrapleural fibrinolysis for 
the treatment of complicated PPEs and empyema suffer many 
methodologic and design limitations. Nevertheless, these 
reports have not shown a survival advantage with the use 
of intrapleural fibrinolysis in adults. However, intrapleural 
fibrinolysis is safe in most of the published studies, has been 
shown to enhance drainage of infected pleural fluid, and may 
still be used in adults who have large collections impeding 
breathing, but a proportion of these patients will ultimately 
need surgery for a definite cure. Streptokinase seems to be 
as effective as urokinase in enhancing drainage of infected 
pleural fluid in adults. There is emerging evidence that a 
combination of intrapleural tPA/DNase is significantly 
superior to tPA or DNase alone or placebo in improving 
pleural fluid drainage in adults with pleural space infection. 
In children, intrapleural thrombolysis has not been shown to 
reduce mortality, but has been shown to enhance drainage of 
infected pleural fluid. Intrapleural urokinase was shown to 
be marginally better when compared with alteplase in treat-
ing pleural space sepsis. Two prospective, randomized trials 
have shown that there is no difference in clinical outcome 
between intrapleural fibrinolysis and VATS for the treatment 
of childhood empyema. Intrapleural fibrinolysis is a more 
cost-effective treatment option compared with VATS and 
should be the primary treatment of choice in children.
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